Stockreport

BioNTech shifts focus toward cancer drug development after earnings, revenue plunge [Globe and Mail, The (Toronto, Canada)]

BioNTech SE - American Depositary Shares  (BNTX) 
PDF BioNTech is targeting 2024 revenues in a range of 2.5 billion to €3.1-billion, depending among other things on regulatory developments and COVID-19 vaccine uptake, it s [Read more]